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ABSTRACT
Background: Liver function tests (LFTs) are frequently requested blood tests which 
may indicate liver disease. LFTs are commonly abnormal, the causes of which can 
be complex and frequently under investigated. This can lead to missed opportunities 
to diagnose and treat liver disease at an early stage. We developed an automated 
investigation algorithm, which would maximise early diagnosis of liver related 
diseases. Our aim was to determine whether this new pathway of care, Intelligent 
Liver Function testing (iLFT) increased diagnosis of liver disease and was cost-
effective. 
Methods: We developed an automated system that further investigated abnormal 
LFTs on initial testing samples to generate a probable diagnosis and management 
plan. 
We integrated an automated investigation algorithm into the laboratory management 
system, based on minimal diagnostic criteria, liver fibrosis estimation, and reflex 
testing for causes of liver disease. This algorithm then generated a diagnosis and/or 
management plan.
A stepped-wedged trial design was utilised to compare LFT outcomes in General 
Practices in the 6 months before and after introduction of the iLFT system. 
Diagnostic outcomes were collated and compared.
Results: Using iLFT, the diagnosis of liver disease was increased by 43%. It was 
cost-effective with a low initial incremental cost-effectiveness ratio (ICER) of £284 
per correct diagnosis, and a saving to the NHS of £3,216 per patient lifetime.
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Conclusions: iLFT increases liver diagnosis, improves quality of care, and is highly 
cost-effective. This can be achieved with minor changes to working practices and 
exploitation of functionality existing within modern laboratory diagnostics systems.
Lay Summary
There is a growing epidemic of advanced liver disease, this could be offset by early 
detection and management. Checking liver blood tests (LFTs) should be an 
opportunity diagnose liver problems, but abnormal results are often incompletely 
investigated. In this study we were able to substantially increase the diagnostic yield 
of the abnormal LFTs using the automated iLFT system. With the addition of referral 
recommendations and management plans, this strategy provides optimum 
investigation and management of LFTs and is cost saving to the NHS.
Introduction
There has been an exponential increase in the number of liver function tests (LFTs) 
requested in general practice.1,2 A proportion are checked for the investigation of 
liver disease but most are for investigating undifferentiated illness, or monitoring non-
hepatic long term health conditions 3–5. It is unknown how significant a solitary 
abnormal LFT result is;1 does it signify current or future liver disease, disease in 
other organs, or is it a temporary phenomenon of little clinical relevance?6
Studies have shown that approximately 20% of initial LFTs are abnormal.1 The 
cause of LFT abnormalities vary geographically and the cost effectiveness of 
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additional testing will vary also. Additional diagnostic tests such as ultrasound or 
screening blood tests may still leave many abnormal LFTs unexplained.2,7 Further 
investigations such as liver biopsy are invasive and expensive.8 Primary care 
guidelines on evaluation of abnormal liver enzyme results in asymptomatic 
individuals do not take the costs to the patient or the health service into account.8,9 
The commonest causes of abnormal LFTs leading to chronic liver disease in the UK 
and most developed countries are non-alcoholic fatty liver disease (NAFLD),10 
alcohol related liver disease (ARLD),11 and hepatitis C virus (HCV) infection.12  All 
pose a considerable economic burden on the health service.13,14 However there are 
many other causes of abnormal LFTs that need to be considered; including biliary 
disease, drug reactions, systemic illness, malignancy and hepatic infections.15,16 
Despite the increasing use of LFTs, patients continue to present with undiagnosed 
end stage liver disease, which may have been preventable by earlier diagnosis.6 
Early detection may improve prognosis and treatment options, whilst diagnostic 
delay may be damaging to patients and to professional reputations. 
There have been few population studies to date that have quantified liver disease 
following abnormal LFTs.17–20 Duh et al 17 quantified the incidence of liver enzyme 
abnormalities in the general population in Massachusetts, USA. There was no long 
term follow-up to eventual liver disease diagnosis. A large cohort study in Korea (n = 
142,055) reported the association between the  LFT serum aminotransferases (AST 
and ALT) and mortality from liver disease indicating that even values that were in the 
upper quartile of the normal range were associated with worse outcome. 1,18 Our 
previous study used electronic case record linkage to diagnose liver disease and this 
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project showed that 20% of all LFTs measured were found to be abnormal with less 
than 10% of these explained by existing liver disease.21 
To investigate this further we studied the outcomes of individuals up to 15 years post 
LFT measurement in primary care.22 Over 60% of the catchment population had 
LFTs measured. A total of 2,189,152 LFTs were first checked in primary care in 
95,992 people. Of these 21·7% were abnormal and 1·26% went on to have a 
diagnosis of chronic liver disease (hepatocellular causes) while 1·61% developed 
biliary disease (including gallbladder and biliary tract disease).
Current practice when managing abnormal LFTs in primary care is variable with GP 
strategies ranging from ignoring abnormal LFT results, repeat sampling, requesting 
additional tests or referring to specialist services.23,24 Recently published guidelines 
advocate more active investigation of abnormal LFTs, but clinical practice does not 
yet reflect this.25 
The iLFT system was developed to promote appropriate investigation of abnormal 
LFTS in primary care by utilising minimum diagnostic criteria, the availability of 
automated tracked analysers and liver fibrosis markers with high negative predictive 
values.
 A working group convened by the Scottish Government Liver Care Pathway 
Advisory group used an extensive literature review and expert opinion to 
achieve professional consensus on minimum diagnostic criteria for liver 
diseases.  Highly specific diagnostic criteria have been identified for each liver 
disease based on a few simple clinical observations e.g. BMI, alcohol intake, 
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presence or absence of metabolic syndrome, and blood test results. This 
allows diagnosis using a minimal range of robust diagnostic criteria but gives 
confidence that those identified do indeed have the disease. The system is 
not designed to put everyone in a diagnostic group, just those that meet the 
criteria. It is designed to fail safe, always defaulting to further clinical 
evaluation if there is diagnostic uncertainty.6
 Technological developments within diagnostic laboratories have led to the use 
of automated tracked analysers where patient samples are passed between 
analysers to deliver a wide repertoire of tests under computer control. In real 
time the system can change a sample’s journey based on the preceding 
results (reflexive testing) i.e. if a result outside of a threshold value is 
detected, the system can use a pre-programmed algorithm to trigger 
additional tests automatically.  Combining results with clinical information 
provided through the electronic ordering system enables the laboratory 
information management system (LIMS) to calculate prognostic indices and 
allocate a suggested diagnosis.
 The crucial point in determining management and need for referral to 
hepatology for expert review and further investigation for the common liver 
diseases is the degree of liver fibrosis or cirrhosis, as many with no fibrosis 
can be treated with life style advice. Non-invasive fibrosis indices are effective 
at excluding significant fibrosis and many of these indices can be calculated 
using routinely available clinical laboratory analytes.26–28
By integrating these three steps we designed a system that enables an intelligent 
automated response to abnormal LFTs results.  This study compares this new 
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intelligent liver function test (iLFT) system to routine clinical practice in primary care. 
We hypothesise that iLFT will deliver early identification of treatable liver disease, 
reduce GP consultations, and be cost-effective.   
Patients and methods
Study population
Patients were purposively recruited from 6 general practices in Tayside, Scotland, 
UK between September 2015 and November 2016 to ensure a mix of urban and 
rural practices. Each practice has an average of five thousand registered patients. 
Consent was sought from each patient who had LFTs sampled in the intervention 
group. The inclusion criteria were people aged 18-75 in whom their GP requested 
LFTs. They were excluded if they had; jaundice, pre-existing liver disease, previously 
known abnormal LFTs, or LFTs required for monitoring of a specific side effect of a 
drug or treatment. Post enrolment clinical record review confirmed absence of 
exclusion criteria and validated BMI and presence of metabolic syndrome. 
Confirmation of alcohol intake was not possible, but was self-reported by the patient 
to the health care professional. 
The study was conducted in accordance with the 1975 Declaration of Helsinki and 
the principles of good clinical practice (GCP). The study was co-sponsored by the 
University of Dundee and NHS Tayside, and was ethically reviewed and approved by 
the East of Scotland Research Ethics Service.
Study design
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A stepped wedge design was used with all six participating practices receiving the 
iLFT intervention. Each practice was randomised to one of three different start dates, 
at monthly intervals. Each practice functioned as their own control in a mixed model 
analysis, over the duration of the trial (six months control, six months intervention). 
See figure S1.
The control population were people with LFTs above the NHS Tayside reference 
limits (see appendix) in the participating practices during the 6 months before the 
iLFT intervention. They were retrospectively assessed, all who fulfilled inclusion and 
exclusion criteria were included as controls. In the intervention arm GPs requesting 
LFTs during the intervention period could select the iLFT option. All patients with 
abnormal LFTs were followed up. 
Outcomes for all subjects in both groups were accessed via their GP records 6 
months after initial LFT sampling, to allow GPs to record and action iLFT 
recommendations. The final liver diagnosis recorded in the GP notes was extracted 
and numbers of visits, referrals, and tests performed during the six months were 
recorded. The control period was scheduled first in all practices to avoid confounding 
by the potential educational effect of iLFT. 
The intervention phase worked as follows:
1. GP requests LFTs on their electronic requesting system. A prompt asks if they 
want to screen for liver disease if LFTs are abnormal.
2. A positive response prompts the GP to enter data about patients’ alcohol 
consumption, BMI and features of metabolic syndrome.
3. If components of the LFT results (Bilirubin, ALT, Alkaline Phosphatase or 
GGT) are above the NHS Tayside reference limits (“abnormal”) this triggers 
  
12
an automated reflexive cascade of additional tests in the laboratory to 
characterise aetiology. These include viral serology (anti HCV antibody, HBV 
surface antigen – positive tests confirmed with PCR), liver immunology (anti-
nuclear antibody, anti-mitochondrial antibody, anti-smooth muscle antibody 
and anti-liver kidney microsomal antibodies), iron studies (ferritin, iron, 
transferrin and percentage saturation of transferrin), alpha 1 anti-trypsin (with 
phenotyping if result of <1.0g/L), and caeruloplasmin. Fibrosis staging 
algorithms (Fib 4 and NAFLD fibrosis score) are also calculated. These 
automatically populate the diagnostic algorithms to identify a relevant 
diagnosis and management plan. There are 31 management plans in total.(6)
4. The report is made available to the GP in real time for them to action. This 
included lifestyle advice for ARLD/NAFLD patients, management plans for 
primary care and referral recommendations for those requiring assessment 
and treatment e.g. autoimmune hepatitis and viral hepatitis. Access to the 
management plans is delivered electronically as web hyperlinks.
5. The study team reviewed patients’ notes 6 months post intervention to 
document the GP recorded diagnosis following receipt of the iLFT outcome 
and management plan. This “final diagnosis” was adjudicated by the GP with 
no input from the study team. 
Primary outcome
Rate of diagnosis of liver disease, inclusive of hepatocellular and biliary tract 
disorders, following detection of abnormal LFTs recorded by the GP
Secondary outcomes
1. Number of GP and patient contacts from the initial LFT sample to diagnosis
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2. Number of referrals to secondary care for diagnosis
3. Cost-effectiveness analysis comparing current clinical practice with the iLFT 
intervention.
 
Statistical Power
The required number of subjects estimated assuming 80% power and a 5% 
significance level for an increase in detection of liver disease from 1% to 2·5% is 
2,658 with a standard before and after study ignoring the stepped wedge design. 
The design effect (DE) reduces numbers required because of the multiple steps of 
repeated measures despite the effect of clustering.29  With 6 monthly steps in order 
to demonstrate a 2·5-fold or more increase in liver disease diagnosis it would require 
only 1284 patients having LFTs measured.  To ensure adequate recruitment 6 
practices were recruited rather than 4, as the loss of a whole practice could 
jeopardise the trial. An increase in the rate of liver diagnosis to the top end of the 
published estimates of 10% has little impact but increases the power of the study.
Statistical Analysis
This stepped wedge design study includes a period where no clusters were exposed 
to iLFT. Subsequently at 4 week intervals the clusters are randomised to receive the 
iLFT intervention. The process continues until all 6 clusters are exposed. Data 
collection continues throughout the study so each cluster contributes to both control 
and intervention outcomes. 
The analysis of primary and secondary outcomes was carried out using non-linear 
mixed effect models. The models incorporated fixed terms for intervention (before 
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versus after), time (monthly interval time periods), and accounted for the correlation 
of patients within practices, and the correlation of repeated measurements over time 
as random effects using the approach of Hussey and Hughes, 2007.30 The models 
were also adjusted for age and gender. Missing data was assumed as missing at 
random (MAR) as mixed models have the advantage of allowing for missing data 
while maintaining the principle of intention to treat (ITT), although we did not expect 
any missing data as the primary outcome is dependent on diagnosis of liver disease 
which is either present or not. These models also allow for adjustment for baseline 
differences. The primary null hypothesis was no difference in the rate before 
compared to after intervention. The analysis incorporated the correlation of patients 
within practices and of repeated measurements over time. Statistical analysis used 
SAS9.4.
Economic analysis
A within-trial analysis explored the incremental cost per correct diagnosis of the iLFT 
intervention compared to control (routine clinical practice), at six months follow-up 
from the perspective of the NHS and Personal Social Services.  Resource use data 
(such as GP visits, blood test requests, ultrasounds, fibroscans, and secondary care 
referrals) was collected during the study for each arm along with the trial primary 
outcome diagnostic data from the stepped wedge design. Unit cost information 31 
was combined with the trial resource use data to estimate the mean cost per patient 
in each arm for price year 2016.  Within study cost-effectiveness was reported as 
incremental cost per correct diagnosis at 6 months. 
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A decision analytic model was developed for the lifetime analysis, reporting the 
discounted incremental cost and QALY gains, for cost year 2016, adhering to the 
NICE reference case.32  The Markov model extrapolated trial outcomes on diagnosis 
to account for the lifetime costs and quality adjusted life year (QALY) impacts of 
Alcoholic Liver Disease (ALD) and Non-Alcoholic Fatty Liver Disease (NAFLD) from 
the iLFT intervention compared to routine clinical practice. 
Results
Recruitment 
In the control group, 490 eligible patients with abnormal LFTs were identified and 
followed up for 6 months after their initial GP appointment. In the intervention group, 
229 patients were recruited, 64 (27·9%) had abnormal LFTs. There were no 
significant differences in age or sex between the two cohorts (Table 1). Recruitment 
continued in the intervention phase for the first four practices until the end of the trial 
in all practices, to increase the number of outcomes. All patients recruited out with 
the step-wedge time windows were excluded from the primary analysis (Table 2). In 
the control phase all eligible patients were identified (490), whilst in the intervention 
phase only those recruited by GPs were included, leading to under recruitment of 
eligible patients. We calculate that the 64 with abnormal LFTs in the intervention arm 
were approximately 13% of all likely eligible patients in the practices. 
Diagnosis outcomes
Final diagnosis was taken as that recorded in the GP notes 6 months after the test. 
GPs could ignore or adjust (possibly due to further information from the patient or 
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clinical examination) the iLFT test suggested diagnoses. This was left to GP 
discretion with no influence from the study team, to replicate real life management of 
results in general practice. Table 4 shows the concordance between iLFT and GP 
diagnosis.  
Table 3 demonstrates the diagnosis outcomes for the control and intervention arms. 
The commonest diagnoses were alcohol related liver disease (ARLD), abnormalities 
secondary to systemic disease, non-alcoholic fatty liver disease (NAFLD) and biliary 
disease across both groups. “iLFT” diagnoses were additionally refined by the use of 
fibrosis algorithms to stage disease, i.e. alcohol related liver disease unspecified in 
the control arm becomes alcohol related liver disease with or without fibrosis. Within 
the fibrosis group 6 patients had advanced fibrosis (FIB4 >3.25 or NAFLD fibrosis 
score >0.676)(33). Figure 1 (and table S1) shows the major diagnostic category 
outcomes, defined by final GP diagnosis, unadjusted for step wedge time windows. 
A hepato-biliary diagnosis of any description was documented in the GP record in 
56% of intervention cases compared to 16% pre-intervention, demonstrating the 
system is effective. The majority of additional diagnoses for the iLFT arm came from 
the groups labelled “Normalised-no diagnosis” and “Not re-checked-not investigated” 
in the control arm (figure 1). The latter is unsurprising as further investigation 
uncovers a diagnosis, however for the former, standard practice would not 
investigate normalised LFTs. Arguably most of these LFTs had not normalised given 
the controversy over the normal range for ALT.(34) 
The study recorded the GP diagnosis as the primary outcome, this did not always 
agree with the suggested iLFT diagnosis, this discrepancy is shown in table 4. 
Overall iLFT supported the GP to a diagnosis in 67% of cases. However, GPs 
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discarded the suggested iLFT diagnosis in 13 cases, of these in 6 there was an 
alternative diagnosis and in 7 no diagnosis was recorded and no action was taken. 
iLFT assigned a diagnosis to 29/64 (45·5%) of the remainder 6 (9%) had fibrosis 
without aetiology and 29/64 (45·5%) had no fibrosis and no diagnosis. On further 
note review, the majority of the latter group had features of NAFLD.  
The primary outcome analysis of the study was performed only on those patients in 
the predefined step-wedge time windows. This reduced the control cohort from 490 
to 486 and iLFT cohort from 64 to 54. The adjusted difference in rate of liver disease 
diagnosis is given in Figure 1 with a highly significant increase of 43% (95% CI 27%, 
59%, p<0·0002) in the iLFT group compared with Controls. For secondary outcomes 
there were significant increases in rates of visits to the GP pre and post diagnosis 
with RR = 2·00 (95% CI 1·37, 2·91) and RR = 3·47 (95% CI 1·63, 7·36) respectively. 
In addition, there was some indication of lower rates of non-liver visits to the GP with 
RR = 0·77 (95% CI 0·59, 0·99), though this only just reached significance. The 
number of nurse visits and blood requests were not significantly increased. The 
overall number of visits was not significantly different.  Referrals to secondary care 
was significantly increased with OR = 8·44 (95% CI 1·99, 35·73). It is important to 
acknowledge that the activity reflected in this data in the control cohort is real world 
practice and not “standard of care” as defined by guidelines, non-investigation of 
>50% of patients alters the comparator considerably.   
Health Economic analysis
Table 6 describes the primary trial outcomes from the stepped wedge sample used 
in the economic analysis, while Table 7 describes the base case economic 
outcomes. iLFT performs better than Control for detecting liver disease (true 
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positive) and identifying healthy people (true negative), resulting in a 51% increase in 
probability of correct diagnosis.  
The within trial analysis resulted in an incremental cost per correct diagnosis 
(including true positive and true negative) of £284. The lifetime model resulted in a 
cost saving with iLFT of £3216 per person and improved effectiveness, with an 
additional 0·021 Quality adjusted life year (QALY) gained. iLFT is not only cost-
effective but a dominant strategy. Figure S2 in the appendix presents the distribution 
of incremental cost and effect outcomes from the probabilistic analysis (1000 
iteration Monte Carlo simulation) on a cost-effectiveness plane. All the simulation 
outcomes fall in southeast quadrant, iLFT is the dominant strategy. iLFT remains the 
dominant strategy across a wide range of willingness to pay thresholds, and at the 
UK threshold of £30,000 per QALY(35)  iLFT has a 100% probability of being cost-
effective.
GP feed back
GP participants (21/23) completed a questionnaire reviewing iLFT.  The majority 
were positive about iLFT and wished to continue to have access, finding it easy to 
use, and feeling it reduced their work load (see supplementary Tables S2 and S3).
Discussion
The purpose of iLFT was to increase the proportion of patients who underwent 
appropriate investigation, achieved a diagnosis, and were correctly managed for 
their condition. The first step of this is clearly to perform the investigations.
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Analysis was performed on the final hepatic diagnosis recorded by the GP, rather 
than the suggested iLFT diagnosis as it is the clinical decision maker the study was 
intended to influence. The Final Diagnosis may well have been suggested by iLFT, 
however using the diagnosis recorded by the GP as final diagnosis affords clinician 
input and reflects the final clinical decision in primary care which determines the 
patient outcome. This biases against the diagnostic rate of iLFT, as several iLFT 
diagnoses were not actioned or recorded by the GP.  GPs have access to additional 
clinical information that may revise the suggested diagnosis, e.g. co-morbid disease 
or changed information e.g. alcohol consumption. They may also regard the 
abnormality as insignificant. The overall GP response to the iLFT diagnostic report 
demonstrates variance. We think that this was due in part to their taking time to 
familiarise themselves with the system and its full potential. Another factor is GPs 
acting appropriately by making a clinical judgement about an individual patient rather 
than accepting the algorithm generated diagnosis. Familiarity with system, further 
education about the reliability, and increased use of iLFT may change some of those 
behaviours and reduce variation in practice. This system should be utilised as an 
investigative tool to suggest diagnoses but does not supersede clinical judgement.  It 
is important to note that the clinical activity in the control cohort is real world practice 
not “gold standard of care” as defined by guidelines. Real world practice is sub-
optimal resulting in non-investigation of over half of patients.21
Importantly, iLFT determines diagnoses in a primary care context allowing informed 
and appropriate referral. The iLFT diagnosis was not based on liver histology, nor 
advanced complex imaging as these modalities do not reflect the early stages of the 
presentation of abnormal LFTs. Instead the iLFT diagnosis was based on the 
algorithm that we have validated and published previously using a minimum data 
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set.6 The consensus process that developed the iLFT algorithm accepted that certain 
diagnosis would require further investigation, including possible liver biopsy, that this 
required referral from primary care and the management plans associated with the 
diagnoses provided a fail safe route to expert review.  
The most striking effect of the iLFT intervention is the increase in liver disease 
diagnosis rate. This is attributable to the fact that all LFT’s were investigated 
automatically in contrast to the 50% or more that were not investigated in the control 
group. In the Control group 59% were not actioned further compared with zero in the 
intervention group. This significantly increased the diagnosis rate by 43% in the 
Intervention group. The benefits of earlier identification of liver disease are evident in 
the lifetime economic model. As detection of liver disease was higher in the 
intervention arm we are certain that disease that would previously have been missed 
has been detected. The success of iLFT depends on early diagnosis and health 
interventions to avert the consequences of missed or late diagnosis of liver disease. 
The economic model reaffirms this rationale, but longer term follow up is needed to 
prove its benefit on overall outcomes. 
Increasing the number of liver diagnoses inevitably increases the number of referrals 
to secondary care. The benefit of iLFT is that the liver diagnoses are stratified to 
management either in primary care or secondary care. Conditions that require 
secondary care input are referred appropriately and those that can safely be 
managed in the community are not referred. The nature of referrals to specialist care 
are therefore more appropriate and this enables suitable allocation of resources. 
Several cases were recommended for referral because of indeterminate fibrosis 
scores. The fibrosis staging tests used in this system; Fib 4 and the NAFLD fibrosis 
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score, are cheap to use and have well validated cut offs to exclude significant 
fibrosis. However they are not highly specific and many patients scoring above the 
cut offs will not have significant fibrosis. In the current system they would default to 
further assessment in secondary care which adds to cost. Additional tests such as 
ultrasound or magnetic resonance based elastography may improve fibrosis 
estimation but would be difficult to automate and the cost would likely be prohibitive. 
The use of a second line biochemical analyte or scoring system, such as ELF which 
has recently been recommended by NICE for use in NAFLD staging,(36) would be 
easy to add into the system. This has the potential to reduce costs and referrals by 
improving fibrosis stratification. 
Our model of immediate investigation is in agreement with new versions of 
international guidelines which previously recommended repeat testing first, as a 
proportion of LFTs normalise. (25,34) Our analysis shows this is flawed on two counts, 
firstly many of those LFTs that apparently normalised still had underlying liver 
disease, a proportion of which had significant fibrotic liver disease. Secondly this 
project demonstrates that immediate screening for aetiology of liver disease 
especially on the index sample is highly cost-effective, this is supported in modelling 
work by Tapper et al. (37)  
The iLFT algorithm reduces future burdens of liver disease by allowing earlier 
interventions, guided by fibrosis scores which highlight those most at risk of future 
liver disease. The impact of this is demonstrated in the lifetime economic analysis 
which models the pathway for detected and undetected ALD and NAFLD. For the 
analysis we assumed the increased diagnosis rate reflected these diseases being 
detected early in the iLFT arm and not investigated further in the Control arm. This 
results in a dominant strategy, lifetime cost savings to the NHS, and overall 
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improvement in quality adjusted life year gains, due to this earlier detection. iLFT is 
costlier compared with current clinical practice due to the additional blood tests, 
scans, and increase in referrals. The increased diagnostic rate results in an ICER 
which is considered highly cost-effective. The short-term additional costs are 
outweighed by the long-term savings to the NHS through earlier identification of ALD 
and NAFLD. These models are based on conservative estimates of impact of 
interventions, but there was little uncertainty in the cost-effectiveness results, in 
almost all modelled scenarios it was the dominant cost saving strategy. We have the 
direct costs of the process so the cost effectiveness analysis is very robust. The 
estimated impacts of diagnosis of HCV, NAFLD and ARLD use established models 
of disease progression and conservative estimates of intervention impact taken from 
the literature. Whilst not a replacement for long term follow up, this methodology is 
the most robust available. 
 The project did not address the reproducibility of this system to other healthcare 
services, where costs and access to the appropriate technology will vary. However 
the systems (or similar systems) used in this study are available globally, so iLFT is 
likely to be applicable and cost-effective in most systems.
Contrary to expectations there was no significant reduction in GP work load (GP and 
nurse visits) in the iLFT arm. This can be explained by findings from the control arm, 
over 50% of LFTs checked were not actioned or followed up. The remaining 50% 
that were actioned required increased GP work load compared to the iLFT arm, the 
50% not actioned or followed up clearly generated no further input. While this pattern 
of only investigating 50% of abnormal LFTs is clearly cheaper in the short term it is 
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costlier in the long term with detrimental impacts for the patient’s quality and length 
of life. Furthermore it is sub-optimal clinical practice to request an investigation and 
then ignore the result when it is abnormal.  
The numbers of participants enrolled into the active phase of the iLFT trial by GPs 
was only a proportion of the total number of LFTs being requested. The study 
exclusion criteria likely account for a large number of these. Research staff were 
able to retrospectively identify all eligible patients in the control arm whereas, in the 
iLFT arm, recruitment required active intervention by the GP. Unfortunately this does 
add some potential bias into our results as it is possible that GPs preferentially 
recruited patients they thought would benefit from the additional testing. 
As with any new system, uptake is often slow due to lack of familiarity and time 
pressures. Additionally, this was overtly a research project, with unknown benefits. In 
a busy clinical practice it is often perceived to be easier to avoid involvement in the 
research.  Uptake of the system was higher later in the study. Which reflected the 
benefit felt by the GP participants, who responded positively to the iLFT system. 
21/23 completed an iLFT questionnaire noting that they wished to continue to have 
access to iLFT. They felt that it was easy to use and reduced their work load (see 
Tables S2 and S3). Feedback on the system was very positive and the vast majority 
of GPs were keen to continue to have access at the end of the study.
Conclusions
Liver disease is increasing in incidence in contrast to many other conditions, 
predominantly driven by Non-alcoholic fatty liver disease. It disproportionately affects 
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people under 65 leading to substantially increased morbidity and mortality. It is clear 
that interventions that lead to early diagnosis and the opportunity to intervene and 
abate disease progression are needed. iLFT delivers this opportunity in primary care 
to the general population at a minimal intervention cost, using existing infrastructure, 
utilising existing clinical pathways.  It is designed for immediate implementation and 
could have impacts in the short term. The iLFT system works, it increases liver 
diagnosis, is cost-effective, and is clearly more effective at diagnosing liver disease 
than the standard of care.
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Table 1. Demographics, alcohol intake and systolic BP measurement.
Characteristics Control Group (n=490) iLFT Group(n=64)
Age, mean [SD] 53 [14·96] 52 [15·05]
Gender % (n) Male 55·1% (270) 59·4% (38)
                       Female 44·9% (220) 40·6% (26)
Body mass index, mean [SD] 30·51 [6·64] 30·46 [3·91]
Alcohol % (n)      0 units/week        32·6% (141) 3·2% (2)
                        1-21 units/week        55·7% (241) 84·1% (53)
                      22-50 units/week        6·2% (27) 4·8% (3)
                         >50 units/week 5·5% (24) 7·9 % (5)
Systolic BP mmHg, mean [SD] 132 [17] 133 [13]
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Table 2. Study recruitment, flow diagram
Control iLFT
Number of LFTs requested in study 
sites during trial
12,181 15,150
Number of subjects with abnormal 
LFTs
490 N/A
Number of iLFT subjects N/A 229
Number of iLFT subjects with 
abnormal LFTs
N/A 64
All cases of abnormal LFT subjects 490 64
Number of subjects included in 
primary outcome stepped wedge 
analysis
486 * 54*
*Patients excluded as recruited out with time windows
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Table 3. Final diagnosis in control and iLFT arm in participants with abnormal 
LFTs
Intervention typeFinal Hepatic 
Diagnosis by GP Control iLFT
 n= % n= %
ALD unspecified 30 6·1 0 0·0
ALD with fibrosis 0 0·0 5 7·8
ALD without fibrosis 0 0·0 5 7·8
Abnormal secondary to 
biliary disease
15 3·1 5 7·8
Abnormal secondary to 
systemic disease
42 8·6 7 10·9
Acute hepatitis 3 0·6 1 1·6
DILI 2 0·4 2 3·1
Gilbert's Syndrome 5 1·0 1 1·6
HBV 1 0·2 1 1·6
HCC 1 0·2 0 0·0
HCV 1 0·2 0 0·0
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NAFLD with fibrosis 1 0·2 3 4·7
NAFLD without fibrosis 1 0·2 9 14·1
NAFLD without 
specification
21 4·3 3 4·7
Primary Biliary 
Cholangitis
0 0·0 1 1·6
Normalised-no 
diagnosis
81 16·5 1 1·6
Not normalised- no 
diagnosis
72 14·7 20 31·3
Not re-checked-not 
investigated
216 44·1 0 0
Total 490  64  
Idiosyncratic drug-induced liver injury (DILI), Alcohol related Liver Disease (ALD), 
Non-Alcoholic Liver diseases (NAFLD), Hepatocellular Carcinoma (HCC). 
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Table 4. iLFT diagnosis vs GP diagnosis; this shows the number of suggested 
iLFT diagnoses discarded by GP and outcomes for patients where iLFT offered 
a description of LFT abnormality with fibrosis assessment but no diagnosis. 
  Patients GP Final Hepatic 
Diagnosis Agreed
GP 
diagnosis 
No diagnosis 
or No Action
iLFT 
suggested diagnosis
29 16 6 7
iLFT descriptive 
LFT's with fibrosis
6 - 4 2
iLFT Descriptive 
LFT's no fibrosis
29 - 17 12
Total Patients 64
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Table 5. Primary and Secondary Analyses of Stepped Wedge subjects 
outcomes based on 6 months before and 6 months after the intervention  
 Adjusted† Intervention effectOutcomes
Estimate (95% CI) p-value
Primary outcome : Difference in 
Rates (Intervention – Controls)
43·43 (27·46, 59·40) <0·0002
Secondary Outcomes RR or OR (95% CI) p-value
Num. of GP visits pre-diagnosis 
(liver)
2·00 (1·37, 2·91) 0·0003
Num. of GP visits post diagnosis 
(liver)
3·47 (1·63, 7·36) 0·0013
Num. of GP visits (non-liver) 0·77 (0·59, 0·99) 0·0496
Num. of Nurse visits within GP 
practice‡
1·24 (0·72, 2·13) 0·4295
 Num. of GP LFT blood requests 
post baseline‡
1·19 (0·71, 2·02) 0·5074
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Num. GP visits pre-diagnosis 
(liver) + GP visits post-diagnosis 
(liver) + GP visits  (non-liver) + 
Nurse visits within GP practice + 
GP LFT blood requests post 
baseline
1·15 (0·98, 1·34) 0·0872
Num. of GP visits pre-diagnosis 
(liver) + GP visits post diagnosis 
(liver) + GP visits (non-liver) + 
Nurse visits within GP practice
1·13 (0·96, 1·34) 0·1392
Num. of GP visits pre-diagnosis 
(liver) + GP visits post-diagnosis 
(liver)+ Nurse visits within GP 
practice
1·48 (1·07, 2·06) 0·0189
 Gastroenterologist referral appts + 
Endocrinologist diabetologist appts 
+ haematology appts‡
8·44 (1·99, 35·73) 0·0040
† Adjusted for time, age, gender and alcohol dependence (Linear mixed model for 
primary outcome and Poisson mixed model for counts).
‡ Modelled using Negative Binomial
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Table 6. Primary diagnostic outcomes using stepped wedge analysis 
population for Control and iLFT arms
Control*
N=486
iLFT*
N=54
N(proportion) N(proportion)
Probability 
difference
(95%CI)**
Proportion of  disease 
diagnosis (true positive)
120(0·25) 38(0·7) 0·45 (0·32, 0·59)
Proportion of  no disease 
diagnosis (true negative)
81(0·17) 12(0·22) 0·06 (-0·06, 0·17)
Proportion of not investigated
213(0·44) 0(0)
-0·44(-0·39, 
0·48)
Proportion of investigated not 
normalised
72 (0·14) 4(0·07)
-0·07(-0·15, 
0·005)
Proportion correct 
diagnosis (true positive & 
true negative)
201(0·41) 50(0·93) 0·51(0·43, 0·59)
*adjusted for age and sex by probit model
** based on bootstrap, 1000 iterations adjusted for age and sex
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Table 7. Economic outcomes: short term and lifetime iLFT vs Control group 
using stepped wedge analysis population
Within trial outcome Lifetime model outcomesInterventions
Within trial 
Mean cost 
(CI95%)
Probability of 
correct 
diagnosis 
(CI95%)
Lifetime 
Mean cost
QALY 
gained
Control £185 0·41 £59,764 8·523
iLFT £328 0·93 £56,545 8·545
Difference 
(CI 95%)
£146 
(£63, £228)
0·51 
(0·43, 0·59)
-£3216 
(-£7643, -£897)
·021 
(·009, ·040)
ICER £284 (£128, £440) iLFT is dominant
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Fig 1. Proportions of major diagnostic outcomes in all patients with abnormal 
LFTs in control and iLFT populations.
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iLFT Highlights
 Utilises the smarter application of existing knowledge and technology.
 iLFT increases diagnosis of liver disease by 43%
 With diagnostic accuracy over 90%
 Delivering earlier identification of treatable liver disease
